Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mini-allografts: ongoing trials in humans.

A M Carella, R Champlin, S Slavin

    Bone Marrow Transplantation
    |March 21, 2000
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Nutritional assessment and medical dietary therapy for management of obesity in patients with non-dialysis chronic kidney disease: a practical guide for endocrinologist, nutritionists and nephrologists. A consensus statement from the Italian society of endocrinology (SIE), working group of the club nutrition-hormones and metabolism; the Italian society of nutraceuticals (SINut), club ketodiets and nutraceuticals "KetoNut-SINut"; and the Italian society of nephrology (SIN).

    Journal of endocrinological investigation·2024
    Same author

    Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors.

    Annals of hematology·2018
    Same author

    Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.

    Leukemia·2017
    Same author

    Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.

    Annals of oncology : official journal of the European Society for Medical Oncology·2017
    Same author

    Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis.

    Leukemia·2016
    Same author

    Pretransplant chest computed tomography screening in asymptomatic patients with leukemia and myelodysplastic syndrome.

    Bone marrow transplantation·2016

    Reduced-intensity conditioning for allogeneic stem cell transplants can enable engraftment with fewer side effects. This approach expands transplant eligibility to older patients and those with organ damage, leveraging graft-versus-leukemia effects.

    Area of Science:

    • Hematology
    • Oncology
    • Immunology

    Background:

    • Allogeneic stem cell transplantation is effective for hematologic malignancies but limited by severe side effects from high-dose conditioning regimens.
    • Current protocols exclude many older patients or those with organ damage, necessitating safer transplant strategies.
    • The graft-versus-leukemia (GVL) effect, observed with donor lymphocyte infusions (DLI), suggests a potential for less intensive conditioning.

    Discussion:

    • Minimally myelosuppressive conditioning aims to facilitate engraftment while minimizing toxicity.
    • Strategies include low-dose total body irradiation (TBI) or fludarabine-based regimens.
    • Post-grafting immunosuppression with agents like cyclosporine, methotrexate, or mycophenolate mofetil is employed.

    Key Insights:

    Related Experiment Videos

  • Reduced-intensity conditioning can achieve successful allogeneic engraftment.
  • This approach broadens the applicability of stem cell transplantation to a wider patient population.
  • Leveraging the GVL effect is crucial for managing malignancy post-transplant.
  • Outlook:

    • Further translational studies are evaluating these less intensive regimens.
    • The goal is to make allogeneic transplantation safer and more accessible.
    • This could significantly improve outcomes for patients with hematologic malignancies.